Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceSin categoríaVideos

MPE announces partnership in EU consortium project CERTAINTY: advancing cancer care through virtual twins in personalised immunotherapy

MPE announces partnership with an international team, including representatives from scientific, industry, and healthcare sectors, as part of the EU-funded research project CERTAINTY, which began in December 2023. The EU consortium “CERTAINTY – A cellular immunotherapy virtual twin for personalized cancer treatment” is being funded by the European Union with almost EUR 10 million over…

Read more

ASH 2023 | Myeloma and AL amyloidosis updates

Myeloma Patients Europe (MPE) attended the 65th American Society of Hematology (ASH) Annual Meeting, the largest haematology congress, held from 9 to 12 December in San Diego (United States). MPE has interviewed haematology experts to summarise the latest myeloma and AL amyloidosis updates.   Prof. Dr. Michel Delforge, Department of Haematology, University Hospital Leuven, Belgium, explains…

Read more

The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myeloma

The European Commission has granted conditional marketing authorisation for elranatamab, also known as Elrexfio® marketed by the pharmaceutical company Pfizer. This follows an earlier positive recommendation from the European Medicines Agency (EMA – the EU drug licensing body) Committee for Medicinal Products for Human Use (CHMP), after which the European Commission had 60 days to…

Read more

Myeloma and AL amyloidosis ASH 2023 preview

The American Society of Hematology (ASH) Annual Meeting, the world’s largest haematology conference, will take place from 9 – 12 December in San Diego, United States. It is a very exciting event for the myeloma and AL amyloidosis clinical and patient community, with all the results from the latest and most important research being presented.…

Read more

EMA CHMP gives positive recommendation to elranatamab for the treatment of relapsed or refractory myeloma

On October 12, 2023, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) gave positive recommendation for the conditional marketing authorisation of elranatamab, also known as Elrexfio. The treatment will be offered as a 40 mg/ml solution for injection. Its active component, elranatamab, is a bispecific monoclonal antibody that…

Read more

A statement from MPE on the situation in Israel and Gaza

MPE and our community are extremely saddened by the ongoing and devastating events in Israel and Gaza. The death of hundreds of innocent people is completely unacceptable, and our deepest sympathy goes out to everyone affected. We know our members are continuing to provide support to patients and their families during this difficult time. All…

Read more
June

July 2026

August
MO
TU
WE
TH
FR
SA
SU
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
Events for 1st July
No Events
Events for 2nd July
No Events
Events for 3rd July
No Events
Events for 4th July
No Events
Events for 5th July
No Events
Events for 6th July
No Events
Events for 7th July
No Events
Events for 8th July
No Events
Events for 9th July
No Events
Events for 10th July
No Events
Events for 11th July
No Events
Events for 12th July
No Events
Events for 13th July
No Events
Events for 14th July
No Events
Events for 15th July
No Events
Events for 16th July
No Events
Events for 17th July
No Events
Events for 18th July
No Events
Events for 19th July
No Events
Events for 20th July
No Events
Events for 21st July
No Events
Events for 22nd July
No Events
Events for 23rd July
No Events
Events for 24th July
No Events
Events for 25th July
No Events
Events for 26th July
No Events
Events for 27th July
No Events
Events for 28th July
No Events
Events for 29th July
No Events
Events for 30th July
No Events
Events for 31st July
No Events